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Abstract
Background: Tumor hypoxia is a known risk factor for reduced response to radiotherapy. The evaluation of
noninvasive methods for the detection of hypoxia is therefore of interest. Osteopontin (OPN) has been discussed as
an endogenous hypoxia biomarker. It is overexpressed in many cancers and is involved in tumor progression and
metastasis.
Methods: To examine the influence of hypoxia and irradiation on osteopontin expression we used different cell
lines (head and neck cancer (Cal27 and FaDu) and glioblastoma multiforme (U251 and U87)). Cells were treated
with hypoxia for 24 h and were then irradiated with doses of 2 and 8 Gy. Osteopontin expression was analyzed on
mRNA level by quantitative real-time RT-PCR (qPCR) and on protein level by western blot. Cell culture supernatants
were evaluated for secreted OPN by ELISA.
Results: Hypoxia caused an increase in osteopontin protein expression in all cell lines. In Cal27 a corresponding
increase in OPN mRNA expression was observed. In contrast the other cell lines showed a reduced mRNA
expression under hypoxic conditions. After irradiation OPN mRNA expression raised slightly in FaDu and U87 cells
while it was reduced in U251 and stable in Cal27 cells under normoxia. The combined treatment (hypoxia and
irradiation) led to a slight increase of OPN mRNA after 2 Gy in U251 (24 h) and in U87 (24 and 48 h) cell lines falling
back to base line after 8 Gy. This effect was not seen in Cal27 or in FaDu cells. Secreted OPN was detected only in
the two glioblastoma cell lines with reduced protein levels under hypoxic conditions. Again the combined
treatment resulted in a minor increase in OPN secretion 48 hours after irradiation with 8 Gy.
Conclusion: Osteopontin expression is strongly modulated by hypoxia and only to a minor extent by irradiation.
Intracellular OPN homeostasis seems to vary considerably between cell lines. This may explain the partly conflicting
results concerning response prediction and prognosis in the clinical setting.
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Background
Tumor hypoxia is a known risk factor for reduced re-
sponse to radiotherapy [1]. In these studies hypoxia was
measured with invasive polarographic O2 needle elec-
trodes. The evaluation of noninvasive methods for the
detection of hypoxia is of interest. One strategy is the
use of imaging modalities like PET/CT or MRI. Common
PET tracers for hypoxia imaging which were used in
clinical trials are 18-F-MISO, 18-F-FAZA and 62-Cu
ATSM [2–4].
Another way to investigate tumor hypoxia is the search
for hypoxia associated biomarkers which can be detected
from blood samples or tumor tissues. Several studies in-
vestigated the role of HIF-1α and its dependent gene
regulation including CA IX and VEGF [1, 5–7]. One of
these so called endogenous hypoxia markers is osteopontin
(OPN) [8], a secreted glycophosphoprotein which is over-
expressed in many cancer types [9]. It plays an important
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role in tumor progression, angiogenesis and metastasis
formation [10]. Furthermore, OPN is a prognostic marker
for different tumor entities in which elevated plasma
levels are associated with an unfavorable prognosis
[11–15]. In head and neck cancer treated with defini-
tive radiotherapy Petrik et al. demonstrated prolonged
overall survival and event free survival in patients with
OPN levels below median [11]. Similar results were shown
by Overgaard et al. and Snitcovsky et al. [13, 16]. However,
the TROG 02.02 phase III trial did not report any correl-
ation between osteopontin levels and tumor control or pa-
tient outcome [17].
To look at possible intervening variables we analyzed
the influence of irradiation on OPN expression under
normoxic and hypoxic conditions in head and neck can-
cer and glioblastoma cell lines.
Methods
Cell culture
The human tumour cell lines Cal 27 (tongue carcinoma),
FaDu (hypopharyngeal carcinoma), U251 and U87 (both
derived from glioblastoma multiforme) were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). Cells were grown in Dulbecco’s
modified Eagle`s medium (DMEM) supplemented with
10 % fetal bovine serum (PAA, Cölbe Germany), 2 mM
L-glutamine and penicillin (100 IU/ml)/streptomycin
(100 μg/ml) under normoxic standard conditions (21 %
O2, 5 % CO2 at 37 °C).
To compare OPN expression under normoxic and
hypoxic standard conditions at mRNA or protein levels
cells were seeded on Petri dishes at a concentration of
8×105/dish (Cal 27) or 1×106/dish (FaDu, U87, U251).
Standard condition for hypoxic treatment of cells is nor-
mally at 0.1 % oxygen concentration in radiobiology.
Afterwards cells were allowed to adhere before part of
them were transferred into a hypoxic glove box (Invivo2
200, Ruskinn technology limited, Leeds, UK) and cul-
tured at 0.1 % O2 (5 % CO2 at 37 °C; FaDu, U87, U251)
or 1.0 % (5 % CO2 at 37 °C; Cal 27, FaDu) for 24 hours.
Since the Cal27 cells did not survive under 0.1 % O2
concentration for more than 24 hours (which is the in-
cubation time required before irradiation) we conducted
the experiments under less hypoxic conditions with 1 %
Fig. 1 Western blot showing OPN protein expression under normoxic (N = 21 % O2) and hypoxic (H = 1 % O2 or 0.1 % O2) conditions 24 h after
irradiation with 0, 2 and 8 Gy in Cal27 (a) and FaDu (b), (c) head and neck cancer cell lines. Hypoxic conditions were 1 % O2 for both cell lines.
FaDu cells were also treated with 0.1 % O2 (c) showing comparable results
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O2. For a better comparability of the hypoxic treatment
in the head and neck cancer cell lines we repeated the
western blot and qPCR analysis in the FaDu cell line
with 1 % O2. In parallel cells were kept under normoxic
conditions. Twenty-four hours later cells were irradiated
at doses of 2 Gy and 8 Gy (still under hypoxic or
normoxic conditions) using a 6MV linear accelerator
(Siemens, Concord, CA, USA) at a dose rate of 2 Gy/min
or left untreated. After 24 or 48 hours post irradiation
growing under standard or hypoxic conditions respect-
ively, cells were harvested for preparing whole-cell lysates
or RNA.
Western blot analysis
Whole-cell lysates were prepared by lysing cells in RIPA
buffer under standard conditions. Proteins were run on
4-12 % Bis-Tris gradient gels (Invitrogen, Karlsruhe,
Germany), electrophoretically transferred to polyacryl-
amide membranes (Invitrogen) and analyzed by Western
blotting. Polyclonal rabbit anti-human-OPN antibody FL-
314 and monoclonal mouse anti-human-HPRT antibody
were obtained from Santa Cruz Biotechnology, Inc.
(Heidelberg, Germany). Mouse monoclonal antibodies
against β-actin and GAPDH were purchased from Sigma
(Deisenhofen, Germany) and abcam (Cambridge, UK).
Detection was achieved using species-specific horserad-
ish peroxidase-coupled secondary antibodies (DAKO,
Hamburg, Germany) and Amersham™ ECL™ Select West-
ern blotting detection reagent (GE Healthcare, Chalfont
St. Giles, Buckinghamshire, UK).
ELISA for osteopontin detection in supernatants
Osteopontin protein levels in the non-concentrated su-
pernatants of cultured cells, collected after indicated du-
rations of hypoxia, with or without irradiation, were
determined by ELISA, using the Human Osteopontin
Assay Kit-IBL (Immuno-Biological Laboratories Co.,
Ltd.) according to the manufacturer’s instructions.
RNA isolation and quantitative real-time PCR (qPCR)
RNA of the cells was isolated using the RNeasy® Mini Kit
as recommended by the manufacturer (Qiagen, Hilden,
Fig. 2 Western blot showing OPN-expression under normoxic (N = 21 % O2) and hypoxic (H = 0.1 % O2) conditions 24 h and 48 h after irradiation
with 0, 2 and 8 Gy in U251 (a) and U87 (b) glioblastoma cell lines
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Germany). Afterwards RNA was reverse transcribed into
cDNA using First Strand cDNA Synthesis Kit (Fermentas
GmbH, St. Leon-Rot, Germany) following the instruc-
tions given by the suppliers. To amplify cDNA coding for
OPN and the housekeeping gene hypoxanthine phos-
phoribosyltransferase (HPRT), quantitative real-time-PCR
was carried out using TaqMan® Gene Expression Assays
(Applied Biosystems, Foster City, CA, USA). To verify that
the hypoxic culture conditions were sufficient CA IX
qPCR analysis was performed in the same way. The cycle
number crossing the threshold was used as the threshold
cycle (Ct). The amount of cDNA in each sample was nor-
malized to the crossing point of the housekeeping gene
hypoxanthine phosphoribosyltransferase (HPRT). Changes
in the expression were detected and quantified using the
comparative CT method (2−ΔΔCt).
Statistics
All experiments were carried out in triplicate and re-
produced 2 times. Data are presented as means (±
standard deviation). Statistical analysis was performed
using ANOVA between groups. Significance level was
set at p < 0.05.
Results
Effect of hypoxia and irradiation on OPN expression -
protein level
Two different head and neck cancer cell lines (tongue
carcinoma cell line, CAL 27 and hypopharyngeal cancer
cell line FaDu) and two glioblastoma cell lines (U251
and U87) were cultured under different oxygen condi-
tions (1 % O2 for Cal27 and FaDU and 0.1 % O2 for
U251 and U87). Furthermore, a possible effect on OPN
expression caused by irradiation (2 Gy or 8 Gy) was in-
vestigated. Twenty-four hours (all cell lines) and 48 hours
(U251, U87) after irradiation, lysates of the different cell
lines were prepared and tested by Western blot analysis
for OPN protein levels. Twenty-four hours after irradi-
ation a clear increase of OPN protein expression was
seen in all cell lines grown under hypoxic conditions
compared with normoxic controls. Except for FaDu and
U251 cells grown at 0.1 % O2, this effect was independ-
ent of additional irradiation (Figs. 1 and 2). Irradiation of
FaDu with doses of 2 and 8 Gy apparently had a weak
inhibitory effect of OPN levels under hypoxic standard
culture conditions (0.1 % O2). This was also seen in
U251 cells under hypoxia and 24 h post irradiation with
Fig. 3 Quantitative real-time RT-PCR data showing OPN RNA expression under normoxic (N = 21 % O2) and hypoxic (H = 1 % O2 or 0.1 % O2)
conditions 24 h after irradiation with 0, 2 and 8 Gy in Cal27 (a) and FaDu (b), (c) head and neck cancer cell lines
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2 Gy. U251 and U87 cells, which survived 48 hours post
irradiation under hypoxic conditions, showed a signifi-
cant increase of OPN expression 48 hours after irradi-
ation compared with cells in the normoxic control
group (Fig. 2). Interestingly, in both glioblastoma cell
lines a trend for a reduced osteopontin content was seen
under normoxic conditions after 48 hours irrespective of
irradiation (Fig. 2). Beta-actin and GAPDH were used as
loading controls, respectively. The missing protein bands
of ß-actin (and GAPDH, data not shown) in lysates of
Cal 27 cells, grown under hypoxic conditions, can be ex-
plained by the altered expression of housekeeping genes
under hypoxia in some cell lines [18, 19].
Effect of hypoxia and irradiation on OPN expression –
mRNA level
To assess hypoxia induced effects alone or in combin-
ation with irradiation (2 Gy or 8 Gy) on OPN mRNA
levels qPCR was performed. Cal 27 cells showed a trend
towards increased OPN mRNA levels (up to 12 fold, p =
0.2) under hypoxic conditions, which was slightly re-
duced by irradiation. In FaDu cells hypoxia (0.1 % O2)
caused an insignificant increase in OPN mRNA levels,
which was hardly influenced by irradiation. Since the
Cal27 cells did not survive under 0.1 % O2 concentration
for more than 24 hours (the time point of irradiation)
we conducted the experiments under less hypoxic condi-
tions with 1 % O2. Otherwise irradiation and growing
the cells 24 h post irradiation would not be possible. For
a better comparability of the hypoxic treatment we re-
peated the western blot and qPCR analysis in the FaDu
cell line with 1 % O2. We observed comparable results
in osteopontin expression whether the cells were treated
with 0.1 % or 1 % O2 in the FaDu cell line (Fig. 3).
In contrast there was a decrease in OPN mRNA levels
in the glioblastoma cell lines when cells were cultured
under standard hypoxia (see Fig. 4: 24 h post irradiation),
which was more pronounced the longer the cells were in
culture (see Fig. 4: 48 h post irradiation) (p-values < 0.05).
Doses of 2 Gy led to a non-significant increase of OPN
mRNA expression under hypoxic conditions (Fig. 4).
To confirm hypoxic culture conditions, quantitative
real-time PCR for CA IX expression (which is HIF-1α
dependent and up-regulated under hypoxia) was per-
formed. FaDu and U251 cells showed a clear increase
(30–60 fold) of CA IX expression under hypoxic condi-
tions. Cal27 and U87 cells reacted to hypoxia with a 2-
fold and 5-fold increase, respectively (data not shown).
Fig. 4 Quantitative real-time RT-PCR data showing OPN RNA expression under normoxic (N = 21 % O2) and hypoxic (H = 0.1 % O2) conditions
24 h and 48 h after irradiation (IR) with 0, 2 and 8 Gy in U251 (a) and U87 (b) glioblastoma cell lines. *marks statistical differences between
normoxic and hypoxic conditions on the corresponding dose levels (ANOVA; p < 0.05)
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Changes in CA IX expression under hypoxia were statis-
tically significant in all cell lines.
Effect of hypoxia and irradiation on OPN secretion into
cell culture medium
For detection of osteopontin we used a commercial
ELISA system without further preparation (e.g. concen-
tration) of the cell supernatants. There was no secreted
osteopontin detectable in the supernatants of the two
head and neck cancer cell lines Cal27 and FaDu (data
not shown). U251 and U87 cells were actively secreting
osteopontin which was reduced under hypoxic condi-
tions at 24 h and 48 h (means time after irradiation). In
U87 cells this reduction reached statistical significance
(p < 0.05). In the same cell line there was a slight in-
crease in OPN concentrations after irradiation with 8 Gy
after 48 hours compared to 0 and 2 Gy under hypoxic
conditions which was not statistically significant (Fig. 5).
Discussion
Osteopontin plays a critical role in cancer progression
by binding and activating different αvβ - integrins and
CD44 receptors. Via intracellular signaling this leads to
an increase in cancer cell motility, enhanced prolifera-
tion, anchor independence growth and other steps ne-
cessary for metastasis formation. A recent overview of
this multifunctional protein and other members of the
matricellular protein family is given by Chong et al. [10].
In head and neck cancer as well as in glioblastoma pa-
tients osteopontin has been shown to have prognostic
impact where high osteopontin plasma levels were asso-
ciated with worse outcome [11, 13, 14]. In previous work
we showed in different cancer cell lines that silencing
osteopontin expression resulted in enhanced radiosensitiv-
ity [20–22]. This was also true for the U251 glioblastoma
cell line where we observed an osteopontin dependent de-
crease in cell proliferation, migration and apoptotic activ-
ity and finally in a reduced clonogenic survival [14].
Induction of OPN after irradiation was seen by Chang et
al. in A549 cells by p53 signaling which in the end led to
an inhibition of the apoptotic pathway and resulted in
more radio-resistant tumor cells [23].
In our experiments tumor hypoxia was associated with
elevated OPN expression. In in-vivo trials osteopontin
expression was correlated with tumor hypoxia measured
invasively with the Eppendorf electrode in head and
neck and lung cancer patients [24, 25]. Hence, osteopon-
tin signaling may serve as an endogenous biomarker for
tumor hypoxia and a possible intrinsic target. In a panel
of standardized in-vitro cell lines we confirmed increased
OPN protein expression during hypoxia. Irradiation itself
did not change this pattern significantly when studied 24
Fig. 5 ELISA from cell culture supernatants showing OPN-concentrations under normoxic (N = 21 % O2) and hypoxic (H = 0.1%O2) conditions
24 h and 48 h after irradiation with 0, 2 and 8 Gy in U251 (a) and U87 (b) glioblastoma cell lines. *marks significant differences between normoxic
and hypoxic conditions with p < 0.05 for 24 and 48 hours
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and 48 hours after hypoxic challenge. This was also ob-
served in a breast cancer cell line after irradiation with
2 Gy [22]. If an increase in OPN expression would have
been observed this could be beneficial for tumor cell sur-
vival and may reduce treatment response. This may result
in an increase in radio-resistance.
Unexpectedly, in glioblastoma cell lines a considerable
decrease in osteopontin secretion (40-85 %) under hyp-
oxic conditions with only a slight increase when cells
were irradiated. A decrease in OPN transcription rates
were seen in our qPCR experiments. The reduction of
transcriptional activity of OPN mRNA might be an ef-
fect of a negative feed-back loop due to intracellular ac-
cumulation of osteopontin protein. This assumption is
supported by the observation that intracellular OPN
protein levels increase while active secretion was re-
duced by hypoxia. An intense literature search for OPN
expression patterns under irradiation and hypoxia did
not reveal a comparable paper in glioblastoma. A recent
paper by our group showed an increased OPN mRNA
expression in glioblastoma tumor tissue compared to ad-
jacent non tumor tissue. This is in contrast to our find-
ings in our cell culture model, since we experienced a
decrease of OPN mRNA in the two glioblastoma cell
lines [26]. To elucidate whether the decrease of OPN
mRNA or the intracellular increase of OPN protein has
an effect on cell proliferation, migration or clonogenic
survival further experiments will be done by our group
in the near future. It would also be interesting to know,
if the reduced secretion of OPN can reduce functional
activity of the cells in an autocrine manner. We could
demonstrate in previously published articles in lung,
breast and endometrial cancer cell lines that silencing
osteopontin expression resulted in reduced cell prolifera-
tion, cell migration and enhanced radiosensitivity [20–22].
This was also true for the U251 glioblastoma cell line
where we observed an osteopontin dependent decrease in
cell proliferation, migration and apoptotic activity and fi-
nally in a reduced clonogenic survival [14].
A different expression pattern was seen in the two
head and neck cancer cell lines. No secretion of osteo-
pontin at baseline and after treatment with hypoxia or
irradiation was detected in cell culture supernatants
(data not shown). Likewise, Hui et al. detected OPN in
supernatants in only one of four evaluated nasopharyn-
geal cell lines. In their hands OPN secretion was not af-
fected by hypoxic treatment [27]. In our study higher
protein levels were correlated with increasing OPN
mRNA expression under hypoxia in Cal27 and to a lesser
degree in FaDu cells. Hypoxia enhanced osteopontin
expression in head and neck cancer cells was already dem-
onstrated by Zhu et al. who described a hypoxia associated
element in the osteopontin promotor region regulated by
a Ras enhanced activator [28].
In a next step we are going to analyze intracellular sig-
naling of osteopontin under these experimental condi-
tions and will evaluate functional activity of the tumor
cells via proliferation, migration and survival assays.
Conclusions
In conclusion, osteopontin expression is strongly modu-
lated by hypoxia and only to a minor extent by irradiation.
Intracellular OPN homeostasis seems to vary considerably
between cell lines and differ between mRNA and protein
expression. This may explain the partly conflicting results
concerning response prediction and prognosis in the clin-
ical setting.
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